Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 1:52 PM
Ignite Modification Date: 2025-12-25 @ 12:42 PM
NCT ID: NCT02080195
Description: Reportable serious adverse events per protocol include: any mortality within the first 100 days after bone marrow transplant (BMT), any graft failures (defined as \<5% donor chimerism) associated with failure of neutrophil recovery to \>500/mm³ by day \~60 after transplantation, and all unexpected events as deemed significant by the PIs. Other events were neither tracked nor reported for this study.
Frequency Threshold: 0
Time Frame: Adverse events were assessed weekly through at least Day 60.
Study: NCT02080195
Study Brief: Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Nonmyeloablative Conditioning and BMT Nonmyeloablative Conditioning and Bone Marrow Transplant in Systemic Lupus Erythematosus patients Cyclophosphamide: Cyclophosphamide (alkylating agent) conditioning regimen and post transplantation cyclophosphamide with matched, partially matched, haplo-identical or unrelated donors Sodium-2-mercapto ethane sulphonate: Antineoplastic detoxifying agent Fludarabine monophosphate: Purine antimetabolite Tacrolimus: Calcineurin inhibitor Mofetil: Immunosuppressant Rabbit antithymocyte globulin: Selective immunosuppressant 0 None 0 1 0 1 View
Serious Events(If Any):
Other Events(If Any):